A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This open-label study will evaluate the safety, tolerability and efficacy of
RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid
arthritis (RA) on background non-biologic DMARDs who have an inadequate response to current
non-biologic DMARDs. Patients will receive 8 mg/kg RoActemra/Actemra as an intravenous
infusion every 24 weeks for a total of 6 infusions. The anticipated time on study treatment
is 24 weeks.